CD40LG and non-small cell lung carcinoma: Finally, a retrospective study conducted in our laboratory brought clear evidence of how the IgM–RF positivity is a strong predictive factor for the development of NSCLC patients’ early progression in response to the treatment with anti-PD-1 immune checkpoint inhibitors (ICIs) [51,61].